CM383 not checked

Keymed Biosciences Co.Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Alzheimer Disease
Main trialPhase 1
“This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.”In the company’s words, NCT07292688 on ClinicalTrials.gov
Other names
Alzheimer Disease

Other drugs for Alzheimer Disease

All 91 drugs for Alzheimer Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Jul 2026 Study of CM383 in Healthy Subjects
Phase 1Recruiting 30 Dec 2026 A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
Phase 1Unknown 30 Jun 2025 Single Dose Escalation Study of CM383 in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CM383

Following is part of Solo: you see every change to CM383 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in